Disease progression modelling from preclinical Alzheimer's disease (AD) to AD dementia.
Disease progression modelling from preclinical Alzheimer's disease (AD) to AD dementia.
复制标题
DOI：
10.1038/s41598-021-83585-3
复制
发表时间：
2021-02-18
影响因子：
4.6
通讯作者：
Seo SW
中科院分区：
文献类型：
--
作者：
Cho SH;Woo S;Kim C;Kim HJ;Jang H;Kim BC;Kim SE;Kim SJ;Kim JP;Jung YH;Lockhart S;Ossenkoppele R;Landau S;Na DL;Weiner M;Kim S;Seo SW
为了在较长的时间间隔内表征阿尔茨海默病（AD）的病程，我们的目的是使用两个独立的队列构建从临床前AD到AD痴呆的整个疾病跨度的病程模型。我们模拟了436例AD连续体患者的进展过程，并研究了载脂蛋白E ε4（APOE ε4）和性别对疾病进展的影响。为了建立一个从临床前AD进展到AD痴呆的模型，我们估计了阿尔茨海默病评估量表-认知子量表13（ADAS-cog 13）评分。当计算每个队列的ADAS-cog 13评分中位数时，从临床前AD到AD导致的MCI的估计时间为7.8年，从临床前AD到AD痴呆的估计时间为15.2年。女性APOE ε4携带者的ADAS-cog 13评分恶化最快，男性APOE ε4非携带者的ADAS-cog 13评分恶化最慢（p < 0.001）。我们的研究结果表明，从临床前AD到AD痴呆的疾病进展模型可能有助于临床医生估计患者在病程中的位置，并提供有关性别和APOE ε4状态的病程变化的信息。
To characterize the course of Alzheimer’s disease (AD) over a longer time interval, we aimed to construct a disease course model for the entire span of the disease using two separate cohorts ranging from preclinical AD to AD dementia. We modelled the progression course of 436 patients with AD continuum and investigated the effects of apolipoprotein E ε4 (APOE ε4) and sex on disease progression. To develop a model of progression from preclinical AD to AD dementia, we estimated Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13 (ADAS-cog 13) scores. When calculated as the median of ADAS-cog 13 scores for each cohort, the estimated time from preclinical AD to MCI due to AD was 7.8 years and preclinical AD to AD dementia was 15.2 years. ADAS-cog 13 scores deteriorated most rapidly in women APOE ε4 carriers and most slowly in men APOE ε4 non-carriers (p < 0.001). Our results suggest that disease progression modelling from preclinical AD to AD dementia may help clinicians to estimate where patients are in the disease course and provide information on variation in the disease course by sex and APOE ε4 status.
登录
查看更多内容
DOI：
10.1016/j.jalz.2015.05.005
发表时间：
2015-07
期刊：
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子：
--
作者：
Aisen PS;Petersen RC;Donohue M;Weiner MW;Alzheimer's Disease Neuroimaging Initiative
通讯作者：
Alzheimer's Disease Neuroimaging Initiative
DOI：
10.1016/j.jalz.2018.04.010
发表时间：
2018-09
期刊：
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子：
--
作者：
Buckley RF;Mormino EC;Amariglio RE;Properzi MJ;Rabin JS;Lim YY;Papp KV;Jacobs HIL;Burnham S;Hanseeuw BJ;Doré V;Dobson A;Masters CL;Waller M;Rowe CC;Maruff P;Donohue MC;Rentz DM;Kirn D;Hedden T;Chhatwal J;Schultz AP;Johnson KA;Villemagne VL;Sperling RA;Alzheimer's Disease Neuroimaging Initiative;Australian Imaging, Biomarker and Lifestyle study of ageing;Harvard Aging Brain Study
通讯作者：
Harvard Aging Brain Study
DOI：
10.1016/j.jalz.2011.03.005
发表时间：
2011-05
期刊：
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子：
--
作者：
McKhann GM;Knopman DS;Chertkow H;Hyman BT;Jack CR Jr;Kawas CH;Klunk WE;Koroshetz WJ;Manly JJ;Mayeux R;Mohs RC;Morris JC;Rossor MN;Scheltens P;Carrillo MC;Thies B;Weintraub S;Phelps CH
通讯作者：
Phelps CH
影响因子：
11.2
作者：
Landau, Susan M.;Mintun, Mark A.;Joshi, Abhinay D.;Koeppe, Robert A.;Petersen, Ronald C.;Aisen, Paul S.;Weiner, Michael W.;Jagust, William J.
通讯作者：
Jagust, William J.
影响因子：
5
作者：
Vivot, Alexandre;Power, Melinda C.;Gross, Alden L.
通讯作者：
Gross, Alden L.